Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Source: SeekingAlpha
2025-12-23 18:08:28 ET
The investment thesis I laid out in my first article about Teva Pharmaceutical ( TEVA ) has finally played out. At the time of that article, TEVA was fluctuating around $16.50-$17.00 and is now above $31.50. ...
Read the full article on Seeking Alpha
For further details see:
Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Medical Intelligence Technologies Inc
NASDAQ: MDCLF
MDCLF Trading
100.0% G/L:
$6.9757 Last:
2,000 Volume:
$0 Open:
MDCLF Latest News
November 11, 2025 02:00:00 am
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
November 10, 2025 12:00:00 pm
Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
February 10, 2025 02:00:00 am
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
